-
公开(公告)号：US20250032620A1
公开(公告)日：2025-01-30
申请号：US18831041
申请日：2024-05-13
Applicant: Nammi Therapeutics, Inc.
Inventor： David Stover , Dhruba Bharali , Bruce A. Hay , Tahmineh Safaie
Abstract: Formulated and/or co-formulated liposomes, lipid nanoparticle (LNP) and solid-lipid nanoparticles (SLNP) comprising TB Prodrugs and methods of making the LNPs and SLNPs are disclosed herein. The TB prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit ALK5. The TB Prodrugs can be formulated and/or co-formulated into a nanocarrier to provide a method of treating cancer, immunological disorders, and other diseases by utilizing a targeted drug delivery vehicle.
-
公开(公告)号：US20240050575A1
公开(公告)日：2024-02-15
申请号：US18445323
申请日：2023-07-10
Applicant: Nammi Therapeutics, Inc.
Inventor： David Stover , Dhruba Bharali , Bruce A. Hay , Tahmineh Safaie
CPC classification number: A61K47/543 , A61P35/00 , A61K9/1277 , A61K9/5192 , A61K31/444 , A61K45/06
Abstract: Formulated and/or co-formulated liposomes (LNP) and solid-lipid nanoparticles (SLNP) comprising TB Prodrugs and methods of making the LNPs and SLNPs are disclosed herein. The TB prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit ALK5. The TB Prodrugs can be formulated and/or co-formulated into a liposome or solid-lipid nanoparticle to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.
-
">
公开(公告)号：US20230270819A1
公开(公告)日：2023-08-31
申请号：US17803703
申请日：2022-10-14
Applicant: Nammi Therapeutics, Inc.
Inventor： David Stover , Dhruba Bharali , Bruce A. Hay , Tahmineh Safaie
CPC classification number: A61K38/177 , A61K47/6911 , A61K47/543 , A61K45/06
Abstract: Formulated and/or co-formulated liposomes comprising TLR prodrugs and/or TLR Lipid Moieties and methods of making the liposomes are disclosed herein. The TLR prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit Toll-Like Receptor (e.g., TLR1/2, TLR4, and/or TLR7). The TLR prodrugs can be formulated and/or co-formulated into a liposome to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.
-
公开(公告)号：US20210260197A1
公开(公告)日：2021-08-26
申请号：US17300063
申请日：2021-02-19
Applicant: Nammi Therapeutics, Inc.
Inventor： David Stover , Dhruba Bharali , Bruce A. Hay , Tahmineh Safaie
Abstract: Formulated and/or co-formulated liposomes (LNP) and solid-lipid nanoparticles (SLNP) comprising TB Prodrugs and methods of making the LNPs and SLNPs are disclosed herein. The TB prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit ALK5. The TB Prodrugs can be formulated and/or co-formulated into a liposome or solid-lipid nanoparticle to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.
-
公开(公告)号：US12059470B2
公开(公告)日：2024-08-13
申请号：US18445174
申请日：2023-05-08
Applicant: Nammi Therapeutics, Inc.
Inventor： David Stover , Dhruba Bharali , Bruce A Hay , Tahmineh Safaie
CPC classification number: A61K47/554 , A61K47/548 , A61K47/549 , A61K47/6911 , A61K47/6929 , A61P35/00
Abstract: Formulated and/or co-formulated nanocarriers (e.g., LNPs and/or SLNPs) comprising PD-1 Prodrugs and methods of making the nanocarriers are disclosed herein. The PD-1 Prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit PD-1-L1/L2. The PD-1 Prodrugs can be formulated and/or co-formulated into a nanocarrier to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.
-
Patent Agency Ranking">
公开(公告)号：US20240123028A1
公开(公告)日：2024-04-18
申请号：US18445604
申请日：2023-11-15
Applicant: Nammi Therapeutics, Inc.
Inventor： David Stover , Dhruba Bharali , Bruce A Hay , Tahmineh Safaie
CPC classification number: A61K38/177 , A61K45/06 , A61K47/543 , A61K47/6911
Abstract: Formulated and/or co-formulated liposomes comprising TLR prodrugs and/or TLR Lipid Moieties and methods of making the liposomes are disclosed herein. The TLR prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit Toll-Like Receptor (e.g., TLR1/2, TLR4, and/or TLR7). The TLR prodrugs can be formulated and/or co-formulated into a liposome to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.
-
公开(公告)号：US11801304B2
公开(公告)日：2023-10-31
申请号：US17300063
申请日：2021-02-19
Applicant: Nammi Therapeutics, Inc.
Inventor： David Stover , Dhruba Bharali , Bruce A Hay , Tahmineh Safaie
CPC classification number: A61K47/543 , A61K9/1277 , A61K9/5192 , A61K31/444 , A61K45/06 , A61P35/00
Abstract: Formulated and/or co-formulated liposomes (LNP) and solid-lipid nanoparticles (SLNP) comprising TB Prodrugs and methods of making the LNPs and SLNPs are disclosed herein. The TB prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit ALK5. The TB Prodrugs can be formulated and/or co-formulated into a liposome or solid-lipid nanoparticle to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.
-
公开(公告)号：US20230226031A1
公开(公告)日：2023-07-20
申请号：US17803774
申请日：2022-11-17
Applicant: Nammi Therapeutics, Inc.
Inventor： David Stover , Dhruba Bharali , Bruce A. Hay , Tahmineh Safaie
IPC: A61K31/444 , A61K47/54 , A61K9/127 , A61K9/51 , A61P35/00
CPC classification number: A61K31/444 , A61K47/543 , A61K9/1277 , A61K9/5192 , A61P35/00
Abstract: Formulated and/or co-formulated nanocarriers (e.g., LNPs and/or SLNPs) comprising ICD Prodrugs and methods of making the nanocarriers are disclosed herein. The ICD prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that induce immunogenic cell death (ICD). The ICD Prodrugs can be formulated and/or co-formulated into a nanocarrier to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.
-
公开(公告)号：US11679141B2
公开(公告)日：2023-06-20
申请号：US17300227
申请日：2021-04-16
Applicant: Nammi Therapeutics, Inc.
Inventor： David Stover , Dhruba Bharali , Bruce A Hay , Tahmineh Safaie
IPC: A61K47/54 , A61K47/69 , A61K31/4164 , A61K38/17 , A61K45/06
CPC classification number: A61K38/177 , A61K45/06 , A61K47/543 , A61K47/6911
Abstract: Formulated and/or co-formulated liposomes comprising TLR prodrugs and/or TLR Lipid Moieties and methods of making the liposomes are disclosed herein. The TLR prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit Toll-Like Receptor (e.g., TLR1/2, TLR4, and/or TLR7). The TLR prodrugs can be formulated and/or co-formulated into a liposome to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.
-
公开(公告)号：US20220080051A1
公开(公告)日：2022-03-17
申请号：US17300655
申请日：2021-09-10
Applicant: Nammi Therapeutics, Inc.
Inventor： David Stover , Dhruba Bharali , Bruce A. Hay , Tahmineh Safaie
Abstract: Formulated and/or co-formulated nanocarriers (e.g., LNPs and/or SLNPs) comprising PD-1 Prodrugs and methods of making the nanocarriers are disclosed herein. The PD-1 Prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit PD-1-L1/L2. The PD-1 Prodrugs can be formulated and/or co-formulated into a nanocarrier to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.
-
-
-
-
-
-
-
-
-
Search Results
22
records
(took 0.016 seconds)
